5,24 $
5,86 % gestern
Nasdaq, 30. Oktober, 21:03 Uhr
ISIN
US0044682039
Symbol
ACHV
Berichte

Achieve Life Sciences, Inc. Aktie News

Neutral
GlobeNewsWire
ein Tag alt
SEATTLE and VANCOUVER, British Columbia, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced it will report its third quarter 2025 financial results and provide a corporate up...
Neutral
GlobeNewsWire
11 Tage alt
New life sciences executive brings more than 25 years of legal expertise spanning clinical and commercial stage biopharmaceutical companies New life sciences executive brings more than 25 years of legal expertise spanning clinical and commercial stage biopharmaceutical companies
Positiv
Seeking Alpha
11 Tage alt
Achieve Life Sciences maintains its 'Buy' rating as the FDA accepts the NDA for cytisinicline for smoking cessation, with a PDUFA date set for June 20, 2026. ACHV's expansion into e-cigarette and vaping cessation is promising, supported by positive Phase 2 ORCA-V1 results and a Commissioner's National Priority Voucher from the FDA. Cytisinicline demonstrated a 2.6x higher quit rate vs. placebo ...
Neutral
GlobeNewsWire
14 Tage alt
Potential First-in-Class Treatment for Nicotine E-cigarette or Vaping Cessation Receives Unprecedented Expedited Review Pathway
Neutral
GlobeNewsWire
28 Tage alt
SEATTLE and VANCOUVER, British Columbia, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cessation, today announced that effective October 1, 2025, Achieve's board of directors approved stock option ...
Neutral
GlobeNewsWire
etwa ein Monat alt
New data address critical treatment gap for millions of Americans with COPD who face unique smoking cessation challenges New data address critical treatment gap for millions of Americans with COPD who face unique smoking cessation challenges
Neutral
GlobeNewsWire
etwa ein Monat alt
Donnelly brings more than 25 years of biopharmaceutical expertise in CMC and regulatory operations Donnelly brings more than 25 years of biopharmaceutical expertise in CMC and regulatory operations
Neutral
GlobeNewsWire
etwa 2 Monate alt
SEATTLE and VANCOUVER, British Columbia, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cessation, today announced Mark Rubinstein, M.D., will assume the role of Interim Chief Medical Officer (CMO)...

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen